Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | SNCA | P37840 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26707681 | 1.00 | PTGS1 (0.54) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL14273794 | 0.79 | PTPN1 (0.49) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL24075809 | 0.78 | PTGS1 (0.62) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL31353034 | 0.78 | PTGS1 (0.62) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL26620748 | 0.75 | LMNA (0.43) | LMNAALDH1A1 | |
| SCHEMBL26620751 | 0.75 | LMNA (0.43) | LMNAALDH1A1 | |
| SCHEMBL4760983 | 0.75 | PTPN1 (0.64) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL14273776 | 0.75 | PTPN1 (0.64) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL3276566 | 0.75 | PTGS1 (0.61) | PTGS1PDE4ASNCAPDE3APTPN1 | |
| SCHEMBL24074922 | 0.75 | PTGS1 (0.58) | PTGS1PDE4ASNCAPDE3APTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807614-B1 | Method for making substituted furan compound embodiments and derivatives thereof | TRIAD NATIONAL SECURITY, LLC (US) | 2023-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807614-B1 | Method for making substituted furan compound embodiments and derivatives thereof | FDPS, FLAD1, BLVRB | PTGS1 2392/4885PDE4A 2987/4885SNCA 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.